SCHEMBL7074460

SCHEMBL7074460

O=C(N[C@@H]1C[C@H]2CC[C@@H]1N2)c1ccc(-c2ccccc2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
S1PR4 O95977 1/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 3/20 0.42
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
PTPN1 P18031 1/20 0.41
PTPN11 Q06124 1/20 0.41
POLB P06746 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375394 1.00 NPC1 (0.44) NPC1RAB9AL3MBTL1S1PR4ALDH1A1
Hydrochloric Acid SCHEMBL7075781 0.99 NPC1 (0.43) NPC1RAB9AL3MBTL1S1PR4ALDH1A1
SCHEMBL7225861 0.91 PTPN1 (0.45) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL7225022 0.91 NPC1 (0.42) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL7225621 0.90 NPC1 (0.41) NPC1RAB9AL3MBTL1S1PR4ALDH1A1
SCHEMBL7233288 0.89 NPC1 (0.46) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL7226185 0.89 NPC1 (0.41) NPC1RAB9AL3MBTL1S1PR4ALDH1A1
SCHEMBL7230430 0.89 RAB9A (0.41) NPC1RAB9AS1PR4ALDH1A1HPGD
SCHEMBL7077992 0.88 MMP13 (0.46) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL7225223 0.88 NPC1 (0.45) NPC1RAB9AL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562816-B2 Alpha 7 nicotine acetylcholine receptor agonist anti-psychotic agent, with reduced side effects PHARMACIA & UPJOHN COMPANY 2003-05-13 US claimed
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-6562816-B2 Alpha 7 nicotine acetylcholine receptor agonist anti-psychotic agent, with reduced side effects PHARMACIA & UPJOHN COMPANY 2003-05-13 US disclosed
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069290-A1 SUBSTITUTED-HETEROARYL-7-AZA[2.2.1] BYCYCLOHEPTANES FOR THE TREATMENT OF DESEASE SULT1E1, UGT1A7, UGT1A1 NPC1 613/4885RAB9A 130/4885L3MBTL1 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.